Genetic Basis and Testing Recommendations for Hypertrophic Cardiomyopathy
1. Genetic Architecture and Epidemiology
Hypertrophic cardiomyopathy (HCM) is the most common genetic cause of cardiomegaly and is driven by mutations in cardiac sarcomere protein genes. The American College of Cardiology (ACC) notes that HCM follows an autosomal‑dominant inheritance pattern with incomplete penetrance and variable expression. Approximately 90 % of cases are inherited, and pathogenic sarcomeric variants are identified in 30‑60 % of patients. [1][2]
The overall prevalence of HCM in the general population is estimated at 1 in 200–500 individuals. Familial clustering is observed in about 60 % of cases, while the remaining 40 % appear sporadic. [2][3]
Predominant causal genes:
Gene(s) Approx. share of genetically‑positive HCM cases Approx. share of all HCM cases MYH7 (β‑myosin heavy chain) & MYBPC3 (myosin‑binding protein C) ~70 % ~40 % TNNT2, TNNI3, TPM1, MYL2, MYL3, ACTC1 (each) 1‑5 % per gene — *These figures are reported by the ACC. [1][3]
Over 1,500 distinct pathogenic variants have been catalogued across the sarcomeric genes, the majority of which are “private” (family‑specific). Earlier surveys documented roughly 200 mutations, underscoring extensive intragenic heterogeneity. [3][1]
2. Phenotypic Modifiers and Age‑Dependent Expression
The clinical phenotype results from a complex interplay among the primary mutation, modifier genes, and environmental factors. [1][4]
Incomplete penetrance: many children < 13 years old who carry pathogenic variants are “silent” carriers with normal echocardiograms (no left‑ventricular hypertrophy). 4
Variable expression: family members harboring the identical disease‑causing mutation can display markedly different cardiac phenotypes, reflecting the influence of modifier genes. [1][4]
Age‑dependent penetrance: left‑ventricular hypertrophy typically emerges during adolescence, with morphological expression usually completed by age 17‑18 years. 4
Adult‑onset minimal hypertrophy: some adults—particularly those with MYBPC3 or TNNT2 mutations—may exhibit minimal or absent hypertrophy despite carrying a pathogenic variant. 4
3. Distinguishing True Genetic HCM from Phenocopies
The ACC emphasizes the need to separate true sarcomeric HCM from phenocopies that mimic cardiomegaly but arise from distinct mechanisms. [5][6]
Metabolic/storage disorders:
- PRKAG2 mutations cause familial LVH with ventricular pre‑excitation and represent a metabolic storage disease, not sarcomeric HCM. [1][7]
- Anderson‑Fabry disease (X‑linked α‑galactosidase deficiency) and mitochondrial myopathies can produce LVH but are classified separately. [1][5]
- Cardiac amyloidosis also mimics HCM phenotypically. 1
Syndromic causes:
- Noonan, LEOPARD, and Costello syndromes should be described as “Noonan syndrome with cardiomyopathy” rather than “Noonan hypertrophic cardiomyopathy.” [5][6]
- Friedreich’s ataxia is another non‑sarcomeric cause of LVH. 1
4. Emerging Genetic Findings in Peripartum Cardiomyopathy (PPCM)
A genome‑wide association study identified a novel locus at chromosome 12p11.22 that increases the risk of PPCM. 8
The frequency of genetic predisposition and familial syndromes in PPCM appears comparable to that in other primary non‑ischemic dilated cardiomyopathies. 8
5. Genetic Testing and Family Screening Recommendations
The ACC recommends genetic testing for every patient with HCM to confirm the diagnosis, define the molecular etiology, and guide cascade screening of relatives. [2][3]
Testing yield:
Family screening algorithm (ACC):
- When a pathogenic variant is identified in the proband, cascade genetic testing should be offered to all first‑degree relatives, irrespective of age.
- Genotype‑positive / phenotype‑negative relatives require longitudinal clinical surveillance with serial echocardiography, as they remain at risk for developing HCM. [4][3]
- Each offspring of an affected individual has a 50 % chance of inheriting the pathogenic variant. 3
6. Clinical Management Pitfalls (ACC Guidance)
Do not label all LVH as “HCM.” Reserve the HCM diagnosis for cases where the disease expression is confined to the heart and is caused by sarcomeric mutations (or when genotype remains unresolved). [5][6]
Absence of increased wall thickness does not exclude a pathogenic HCM mutation; no minimum LV wall thickness is required for a genotype‑positive diagnosis. 4
Age‑dependent penetrance: Children and young adults may carry pathogenic variants without echocardiographic evidence of hypertrophy; they should still be considered at risk. 4
PRKAG2‑related hypertrophy must be managed according to its specific disease pathway, not using HCM risk‑assessment data. [1][7]
Cardiomegaly Causes and Diagnosis
Primary Cardiac Causes
- The American College of Cardiology recommends that Hypertrophic Cardiomyopathy (HCM) be characterized by left ventricular wall thickness ≥15 mm in adults, which cannot be explained solely by loading conditions 9, 10
- HCM is most commonly caused by mutations in sarcomere protein genes, particularly MYH7 and MYBPC3, and can present with various patterns of left ventricular hypertrophy, most commonly affecting the basal anterior septum 10
- Dilated Cardiomyopathy (DCM) is characterized by ventricular dilatation, systolic dysfunction, and either normal or reduced wall thickness, and is associated with increased diastolic and systolic wall stress, neurohormonal activation, and biventricular enlargement 11
- Restrictive Cardiomyopathy is characterized by normal or reduced ventricular chamber size with biatrial enlargement, and causes include amyloidosis, sarcoidosis, hemochromatosis, and familial restrictive cardiomyopathies 12
- Myocardial ischemia and infarction can lead to cardiac remodeling and subsequent cardiomegaly, with atherosclerosis accelerated by conditions like diabetes mellitus through vascular smooth muscle cell proliferation and inflammation 13, 14
- Chronic valve disorders can cause pressure or volume overload leading to cardiac chamber enlargement 11
Systemic Disorders
- Diabetes Mellitus can cause diabetic cardiomyopathy with left ventricular hypertrophy, even in the absence of coronary artery disease, characterized by diastolic dysfunction in 40-75% of patients with diabetes, and mechanisms include insulin resistance, hyperinsulinemia, formation of advanced glycation end products, and activation of the renin-angiotensin-aldosterone system 13, 14
- Pheochromocytoma is associated with left ventricular hypertrophy that may resolve with treatment of the underlying condition 15, 16
- Anabolic steroids, tacrolimus, and hydroxychloroquine can cause left ventricular hypertrophy 15, 16, 17
- Glycogen storage diseases, mitochondrial diseases, lysosomal storage diseases, and amyloidosis are genetic disorders that can cause cardiomegaly 15, 17
- Infants of diabetic mothers may develop transient ventricular hypertrophy, and various malformation syndromes (Noonan, LEOPARD, Costello) can also cause cardiomegaly 15, 16
Pathophysiological Mechanisms
- Pressure Overload causes concentric hypertrophy as the heart works against increased resistance 11
- Volume Overload leads to eccentric hypertrophy with increased myocyte length and chamber dilation 11
- Metabolic Dysfunction is characterized by energy starvation of cardiomyocytes due to impaired glucose utilization and increased reliance on fatty acid metabolism 13, 14
- Fibrosis is characterized by increased collagen deposition and cross-linking leading to myocardial stiffness and impaired cardiac relaxation 13, 14
- Neurohormonal Activation contributes to cardiac hypertrophy and fibrosis through the renin-angiotensin-aldosterone system 13, 14
Clinical Approach to Diagnosis
- The European Heart Journal recommends that imaging is essential for diagnosis, with cardiomegaly defined as structural enlargement of the heart detected by echocardiography 10 or cardiac MRI 11
- When cardiomegaly is detected, a systematic search for the underlying cause should be conducted, including evaluation of family history 15, assessment of non-cardiac symptoms and signs 15, ECG abnormalities 16, laboratory tests 16, and multi-modality cardiac imaging 15, 9
- In adults with unexplained left ventricular wall thickness ≥15 mm, consider HCM and evaluate for genetic and non-genetic causes 15, 9, 10
- In patients with diabetes, be alert for signs of diabetic cardiomyopathy, especially diastolic dysfunction 13, 14